 |
NP Pulse: The Voice of the Nurse Practitioner (AANP)Author: American Association of Nurse Practitioners (AANP) Language: en Genres: Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
167.The Science and Strategy of Obesity Management (CE)
Episode 167
Wednesday, 17 December, 2025
Join endocrinology experts Sara MacLeod and Shannon Idzik as they explore the science and strategy behind effective obesity care, offering practical, evidence-based insights clinicians can apply right away. From navigating treatment options like lifestyle interventions, medications and surgery to fostering stigma-free, patient-centered conversations, this episode delivers real tools for improving outcomes. Whether you’re new to obesity management or looking to enhance your clinical approach, this discussion will inspire confidence and compassion in your practice. Objectives Evaluate clinical trial data providing evidence for the current obesity treatment landscape. Examine the pharmacotherapies for treatment of obesity. Summarize lifestyle factors and behavior change options available for people living with obesity, addressing stigma and bias. Develop a treatment plan for patients living with obesity that addresses their individual comorbidities, clinical risks and personal goals. Learners may claim CE credit for this program through Dec. 31, 2026, by participating in the full multi-module Clinical Advantage: Endocrinology Certificate for Advanced Practice Providers program available here. A participation code will be provided at the end of the podcast — make sure to write this code down. Once you have listened to the podcast and have the participation code, return to this activity in the AANP CE Center. Click on the "Next Steps" button of the activity and: Enter the participation code that was provided. Complete the posttest. Complete the other modules of the Clinical Advantage: Endocrinology Certificate for Advanced Practice Providers program. Complete the overall program evaluation. This activity is supported by independent educational grants from Ascendis Pharma Inc., Novo Nordisk Inc., and Xeris Pharmaceuticals, Inc.
